| 中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
|---|---|---|---|---|
| —— | (3R,11aS)-11a-methyl-3-phenyl-2,3,11,11a-tetrahydro[1,3]oxazolo[2,3-b][3]benzazepin-5(6H)-one | 1061681-25-1 | C19H19NO2 | 293.365 |
| —— | (3R,6S,11aR)-6,11a-dimethyl-3-phenyl-2,3,11,11a-tetrahydro[1,3]oxazolo[2,3-b][3]benzazepin-5(6H)-one | 1340590-06-8 | C20H21NO2 | 307.392 |
| —— | (3R,6S,11aR)-6-ethyl-11a-methyl-3-phenyl-2,3,11,11a-tetrahydro[1,3]oxazolo[2,3-b][3]benzazepin-5(6H)-one | 1340590-08-0 | C21H23NO2 | 321.419 |
| —— | (3R,11aR)-6,6,11a-trimethyl-3-phenyl-2,3,11,11a-tetrahydro[1,3]oxazolo[2,3-b][3]benzazepin-5(6H)-one | 1340590-16-0 | C21H23NO2 | 321.419 |
| —— | (3R,6S,11aR)-6-allyl-11a-methyl-3-phenyl-2,3,11,11a-tetrahydro[1,3]oxazolo[2,3-b][3]benzazepin-5(6H)-one | 1340590-10-4 | C22H23NO2 | 333.43 |
| —— | (3R,6S,11aR)-6-benzyl-11a-methyl-3-phenyl-2,3,11,11a-tetrahydro[1,3]oxazolo [2,3-b]-[3]-benzazepin-5(6H)-one | 1061681-41-1 | C26H25NO2 | 383.49 |
| —— | (3R,11aR)-6,6-diethyl-11a-methyl-3-phenyl-2,3,11,11a-tetrahydro[1,3]oxazolo[2,3-b][3]benzazepin-5(6H)-one | 1340590-18-2 | C23H27NO2 | 349.473 |
| —— | (3R,11aR)-11a-methyl-3-phenyl-2,3,11,11a-tetrahydrospiro[[1,3]oxazolo[2,3-b][3]benzazepine-6,1'-cyclopentan]-5-one | 1340590-24-0 | C23H25NO2 | 347.457 |
| —— | (3R,11aR)-11a-methyl-3-phenyl-2,3,11,11a-tetrahydrospiro[[1,3]oxazolo[2,3-b][3]benzazepine-6,1'-cyclohexan]-5-one | 1340590-26-2 | C24H27NO2 | 361.484 |
The tricyclic oxazolidines trans-4 and cis-4 were interconverted upon treatment with allyltrimethylsilane/ TiCl4. The oxazolidine trans-4 was diastereoselectively reacted with PhMgBr to yield the 4,4-disubstituted 3-benzazepinone 6, along with two side products. An X-ray crystal structure analysis of 6 proved the (R)-configuration of the stereogenic center C-4 and thus the retention of configuration. Reduction of 6 with AlCl3/LiAlH4 (1/3) followed by hydrogenolysis with H2, Pd/C resulted in the formation of enantiomerically pure 2-methyl-2-phenyl-tetrahydro-3-benzazepine 11 which has a moderate affinity (Ki = 496 nM) to the PCP binding site of the NMDA receptor.